Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. [electronic resource]
Producer: 20010614Description: 961-6 p. digitalISSN:- 1524-4539
- Abciximab
- Angioplasty, Balloon, Coronary -- adverse effects
- Antibodies, Monoclonal -- therapeutic use
- Coronary Disease -- complications
- Demography
- Diabetes Complications
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Hemorrhage -- etiology
- Heparin -- adverse effects
- Humans
- Immunoglobulin Fab Fragments -- therapeutic use
- Incidence
- Middle Aged
- Randomized Controlled Trials as Topic -- statistics & numerical data
- Risk Assessment
- Risk Factors
- Thrombosis -- etiology
- Treatment Outcome
- Whole Blood Coagulation Time
No physical items for this record
Publication Type: Journal Article; Meta-Analysis
There are no comments on this title.
Log in to your account to post a comment.